modelR06AX28
Extends from Pharmacokinetic.Models.PK_1C_enteral.
Information
| name: | Rupatadine | |
| ATC code: | R06AX28 | route: | oral |
| compartments: | 1 | |
| dosage: | 10 | mg |
| volume of distribution: | 652 | L |
| clearance: | 13.1 | L/h |
| other parameters in model implementation | ||
Rupatadine is a second-generation antihistamine and platelet-activating factor (PAF) antagonist used primarily for the symptomatic treatment of allergic rhinitis and urticaria. It is an orally active, non-sedating agent that is approved and available in many countries for these indications.
Pharmacokinetics
Pharmacokinetic parameters reported for healthy adult volunteers, both male and female, after a single oral dose administration.
References
Santamaria, E, et al., & Valle, M (2021). Rupatadine Oral Solution Titration by Body Weight in Paediatric Patients Suffering from Allergic Rhinitis: A Population Pharmacokinetic Study. Clinical pharmacology : advances and applications 13 115–122. DOI:10.2147/CPAA.S312911 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34135645
Xiong, Y, et al., & Liu, M (2016). CYP3A5*3 and MDR1 C3435T are influencing factors of inter-subject variability in rupatadine pharmacokinetics in healthy Chinese volunteers. European journal of drug metabolism and pharmacokinetics 41(2) 117–124. DOI:10.1007/s13318-014-0236-3 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25427746
Peña, J, et al., & Merlos, M (2008). Antihistaminic effects of rupatadine and PKPD modelling. European journal of drug metabolism and pharmacokinetics 33(2) 107–116. DOI:10.1007/BF03191027 PUBMED:https://pubmed.ncbi.nlm.nih.gov/18777946
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)